Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma
The use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival of metastatic melanoma patients. Nevertheless, half of the patients still develop resistance within the first year of therapy. Therefore...
Spremljeno u:
| Glavni autori: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2023-06-01
|
| Serija: | Antioxidants |
| Teme: | |
| Online pristup: | https://www.mdpi.com/2076-3921/12/6/1313 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|